NASDAQ:VXRT - Vaxart News Headlines

Sign in or create an account to add this stock to your watchlist.
Get Started
$1.93 0.00 (0.00 %)
(As of 02/18/2019 04:00 PM ET)
Previous Close$1.93
Today's Range$1.93 - $2.02
52-Week Range$1.65 - $8.05
Volume18,933 shs
Average Volume62,073 shs
Market Capitalization$13.78 million
P/E RatioN/A
Dividend YieldN/A
Beta0.84

Headlines

Vaxart (NASDAQ VXRT) News Headlines

Source:
DateHeadline
Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate UpdateVaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - February 7 at 11:31 AM
Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018Vaxart to Present at World Vaccine and Immunotherapy Congress West Coast 2018
finance.yahoo.com - November 28 at 11:05 AM
Vaxart Announces Third Quarter 2018 Financial Results and Provides Corporate UpdateVaxart Announces Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 11:00 AM
Vaxart’s Flu Vaccine Looks Promising, But Its Future Is UncertainVaxart’s Flu Vaccine Looks Promising, But Its Future Is Uncertain
finance.yahoo.com - October 16 at 10:23 AM
Vaxarts Flu Vaccine Superior to Sanofis Fluzone, Shares UpVaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
finance.yahoo.com - October 5 at 3:28 PM
Today’s Research Reports on Stocks to Watch: Guardant Health and VaxartToday’s Research Reports on Stocks to Watch: Guardant Health and Vaxart
finance.yahoo.com - October 5 at 10:16 AM
Vaxart's stock soars after upbeat results from oral flu vaccine trialVaxart's stock soars after upbeat results from oral flu vaccine trial
finance.yahoo.com - October 4 at 3:28 PM
Vaxarts stock soars after upbeat results from oral flu vaccine trialVaxart's stock soars after upbeat results from oral flu vaccine trial
www.marketwatch.com - October 4 at 10:04 AM
New Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal ImmunityNew Data from Phase 2 Flu Challenge Study Demonstrates Vaxart’s Oral H1 Flu Vaccine Generated Protective Mucosal Immunity
finance.yahoo.com - October 4 at 10:04 AM
Vaxart Announces Second Quarter 2018 Financial Results and Corporate UpdateVaxart Announces Second Quarter 2018 Financial Results and Corporate Update
finance.yahoo.com - August 9 at 10:52 AM
Vaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation InsightVaxart Announces Publication of the Phase 1 Results of its Oral Norovirus Tablet Vaccine in Journal of Clinical Investigation Insight
finance.yahoo.com - July 12 at 10:04 AM
Oral RSV Vaccine - Preclinical Data Published in VaccineOral RSV Vaccine - Preclinical Data Published in Vaccine
finance.yahoo.com - June 27 at 9:42 AM
Vaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of CondylomaVaxart Reports Topline Results from Phase 2 Trial of Teslexivir™ for the Treatment of Condyloma
finance.yahoo.com - June 4 at 8:53 AM
Vaxart to Present at ASM Microbe 2018Vaxart to Present at ASM Microbe 2018
finance.yahoo.com - June 1 at 8:57 AM
Vaxart to Present at the Jefferies 2018 Global Healthcare ConferenceVaxart to Present at the Jefferies 2018 Global Healthcare Conference
finance.yahoo.com - June 1 at 8:57 AM
Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?Was Vaxart Inc’s (NASDAQ:VXRT) Earnings Growth Better Than The Industry’s?
finance.yahoo.com - May 31 at 3:23 PM
Vaxart Announces First Quarter 2018 Financial Results and Corporate UpdateVaxart Announces First Quarter 2018 Financial Results and Corporate Update
finance.yahoo.com - May 16 at 8:22 AM
Vaxart Announces $5 Million Inavir® Revenue MilestoneVaxart Announces $5 Million Inavir® Revenue Milestone
finance.yahoo.com - April 20 at 3:21 PM
Vaxart Appoints Brant Biehn as Senior Vice President, Commercial OperationsVaxart Appoints Brant Biehn as Senior Vice President, Commercial Operations
finance.yahoo.com - April 19 at 3:22 PM
Vaxart to Present at Two Upcoming Medical MeetingsVaxart to Present at Two Upcoming Medical Meetings
finance.yahoo.com - April 17 at 7:25 AM
Vaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine CongressVaxart Announces Oral Presentation of Clinical Data from Oral Influenza Vaccine Program at the World Vaccine Congress
finance.yahoo.com - April 3 at 6:54 AM
Who Really Owns Vaxart Inc (NASDAQ:VXRT)?Who Really Owns Vaxart Inc (NASDAQ:VXRT)?
finance.yahoo.com - March 22 at 3:18 PM
Vaxart Expands Intellectual Property Portfolio With U.S. Patent AllowanceVaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance
finance.yahoo.com - March 7 at 3:18 PM
Vaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious DiseasesVaxart to Present Clinical Data From Oral Norovirus Vaccine Program at International Congress on Infectious Diseases
finance.yahoo.com - March 2 at 3:18 PM
This page was last updated on 2/18/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital Explained
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel